Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Patient‐ and Cell Type‐Specific Heterogeneity of Metformin Response
Barron, Matthew, Aubry, Marie Christine, Wigle, Dennis A. , Asiedu, Michael K.

Mayo Clinic

Basic & Clinical Pharmacology & Toxicology | September 1, 2017 | Volume: 122 | Issue: 2 | Pages: 214-222

10.1111/bcpt.12898 | PMID 28862803 Get It

AbstractMost FDA‐approved drugs are not equally effective in all patients, suggesting that identification of biomarkers to predict responders to a chemoprevention agent will be needed to stratify patients and achieve maximum benefit. The goal of this study was to investigate both patient‐specific and cell context‐specific heterogeneity of metformin response, using fibroblast cell lines and induced pluripotent stem cells differentiated into lung epithelial lineages. We performed cell survival analysis, transcriptome and whole exome sequencing analysis on both patient‐derived cell lines and cancer cell lines to assess differential metformin response and identify response genes. We found differences in response to metformin treatment across a variety of cell lines and cellular contexts, suggesting that heterogeneity may be patient‐ and cell type‐specific. Gene expression profiling and analysis of metformin‐sensitive and metformin‐resistant cells identified differentially expressed genes that may be able to stratify patients into metformin responders and non‐responders. Sequencing analysis found genomic alterations that correlated with metformin response. These results suggest that the identification of genomic biomarkers for patients who may respond to metformin treatment can provide an opportunity for individualizing metformin chemoprevention in the clinical setting.
Quality Improvement Initiative to Reduce Pediatric Intensive Care Unit Noise Pollution With the Use of a Pediatric Delirium Bundle
Kawai, Yu , Weatherhead, Jeffrey , Traube, Chani , Owens, Tonie, Shaw, B., Fraser, Erin J., Scott, Annette, Wojczynski, Melody R., Slaman, Kristen L., Cassidy, Patty M., Baker, Laura A. , Shellhaas, Renée A. , Dahmer, Mary K. , Shever, Leah L. , Malas, Nasuh , Niedner, Matthew , Shellhaas, Renée A , Kawai, Yu

Mayo Clinic

Journal of Intensive Care Medicine | September 1, 2017 | Volume: 34 | Issue: 5 | Pages: 383-390

10.1177/0885066617728030 | PMID 28859578 Get It

Objectives: Noise pollution in pediatric intensive care units (PICU) contributes to poor sleep and may increase risk of developing delirium. The Environmental Protection Agency (EPA) recommends <45 decibels (dB) in hospital environments. The objectives are to assess the degree of PICU noise pollution, to develop a delirium bundle targeted at reducing noise, and to assess the effect of the bundle on nocturnal noise pollution. Methods: This is a QI initiative at an academic PICU. Thirty-five sound sensors were installed in patient bed spaces, hallways, and common areas. The pediatric delirium bundle was implemented in 8 pilot patients (40 patient ICU days) while 108 non-pilot patients received usual care over a 28-day period. Results: A total of 20,609 hourly dB readings were collected. Hourly minimum, average, and maximum dB of all occupied bed spaces demonstrated medians [interquartile range] of 48.0 [39.0-53.0], 52.8 [48.1-56.2] and 67.0 [63.5-70.5] dB, respectively. Bed spaces were louder during the day (10AM to 4PM) than at night (11PM to 5AM) (53.5 [49.0-56.8] vs. 51.3 [46.0-55.3] dB, P < 0.01). Pilot patient rooms were significantly quieter than non-pilot patient rooms at night (n=210, 45.3 [39.7-55.9]) vs. n=1841, 51.2 [46.9-54.8] dB, P < 0.01). The pilot rooms compliant with the bundle had the lowest hourly nighttime average dB (44.1 [38.5-55.5]). Conclusions: Substantial noise pollution exists in our PICU, and utilizing the pediatric delirium bundle led to a significant noise reduction that can be perceived as half the loudness with hourly nighttime average dB meeting the EPA standards when compliant with the bundle.
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Northfelt, Don W., Mahr, Michael A. , Ralya, Andrew T., Kuffel, Mary J., Buhrow, Sarah A. , Safgren, Stephanie L. , McGovern, Renee M., Black, John L. , Dockter, Travis , Haddad, Tufia C. , Erlichman, Charles , Adjei, Alex A. , Visscher, Dan W., Kipp, Benjamin R. , Liu, Minetta C. , Hawse, John R. , Doroshow, James H. , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Élez, Elena , Reid, Joel M. , Kuffel, Mary, Black, John, Haddad, Tufia, Visscher, Dan, Chalmers, Zachary R, Frampton, Garrett, Ingle, James N. , Safgren, Stephanie L , Goetz, Matthew P. , Suman, Vera J. , Chalmers, Zachary Rockow , Frampton, Garrett M. , Elez, Elena

Mayo Clinic

Journal of Clinical Oncology | August 30, 2017 | Volume: 35 | Issue: 30 | Pages: 3391-3400

10.1200/jco.2017.73.3246 | PMID 28854070 Get It

Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor–positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 design and expansion at 40, 80, and 100 mg per day. Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day and expansion]) was sequenced. Results Of 41 enrolled patients, 38 were evaluable for MTD determination. Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen (n = 15). Patients received endoxifen once daily at seven dose levels (20 to 160 mg). Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations > 1,900 ng/mL. Endoxifen clearance was unaffected by CYP2D6 genotype. One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus). Overall clinical benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (95% CI, 13.4% to 43.1%) including prior tamoxifen progression (n = 3). cfDNA mutations were observed in 13 patients ( PIK3CA [n = 8], ESR1 [n = 5], TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutations; median, 61 v 132 days; log-rank P = .046). Clinical benefit was observed in those with ESR1 amplification (tumor; 80 mg/day) and ESR1 mutation (cfDNA; 160 mg/day). Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53, and AKT) were undetected by cfDNA, whereas cfDNA mutations ( ESR1, TP53, and AKT) were undetected by biopsy. Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.
Comparison of Bioavailability of Single‐Dose Extended‐Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery
Krieger, Carrie A., Cunningham, Julie L. , Langman, Loralie J., Grothe, Karen, Clark, Matthew M. , Dierkhising, Ross , Reid, Joel M. , Grothe, Karen B, Dierkhising, Ross A

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 28, 2017 | Volume: 37 | Issue: 11 | Pages: 1374-1382

10.1002/phar.2022 | PMID 28845898 Get It

Study Objective The extended‐release ( ER ) form of venlafaxine is preferred because of improved patient adherence, but the immediate‐release (IR) form is frequently used after Roux‐en‐Y gastric bypass ( RYGB ) surgery because of concerns for malabsorption. The objective of this study was to determine whether a statistically significant and predictable change in the bioavailability of venlafaxine ER capsules occurs after RYGB . Design Prospective nonblinded single‐dose pharmacokinetic study. Setting Clinical research unit at a large tertiary care medical practice. Patients Ten adult pre–bariatric surgery patients who met the criteria for noncomplicated RYGB were enrolled and served as their own controls. Interventions Patients were administered one venlafaxine ER 75‐mg capsule at two visits—the first visit at least 1 week before undergoing RYGB and the second visit 3–4 months after RYGB . Blood samples were collected at predetermined intervals over 48 hours after each dose, and the pharmacokinetics of venlafaxine were measured. Measurements and Main Results Plasma levels of venlafaxine and its primary metabolite, O ‐desmethylvenlafaxine ( ODV ), were compared at baseline and 3–4 months after RYGB . The areas under the serum concentration–time curves from 0–24 hours ( AUC 0–24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB . Using a bioequivalence approach, differences in pre‐ RYGB and post‐ RYGB values of AUC 0–24 , peak serum concentration, and time to peak serum concentration were not statistically significant for either venlafaxine or ODV. Conclusion This study suggests that RYGB does not significantly alter the amount of venlafaxine or its active metabolite, ODV , absorbed from a venlafaxine ER capsule or the time over which it is absorbed.
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy M. , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Inman, Brant A. , Milowsky, Matthew I. , Boyd, Alan , Treasure, F. Peter, Gregory, Gillian , Sawutz, David G., Parker, Nigel, Dinney, Colin P. , Canter, Daniel J, Karsh, Lawrence I, Woods, Michael E. , Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N, Inman, Brant A , Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Ylä-Herttuala, Seppo

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 30 | Pages: 3410-3416

10.1200/jco.2017.72.3064 | PMID 28834453 Get It

Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Provider Approachability: An All-Staff Survey Approach to Creating a Culture of Safety
Deyo-Svendsen, Mark , Palmer, Karl B., Albright, Jill K., Phillips, Michael R., Schilling, Keith A., Svendsen, Matthew E. Cabrera, Albright, Jill , Svendsen, Matthew Cabrera

Mayo Clinic

Journal of Patient Safety | August 18, 2017 | Volume: 15 | Issue: 4 | Pages: e64-e69

10.1097/pts.0000000000000409 | PMID 28820796 Get It

Objectives A culture-of-safety survey of our hospital staff revealed fear-based reluctance to question those in authority. We aimed to examine provider approachability (words and actions that promote trust and reduce or eliminate fear of interaction). Methods Providers and staff completed an anonymous facility-wide survey (survey 1) regarding perceptions of provider approachability. Results were safely communicated to providers, and improvement resources were offered. A follow-up survey (survey 2 [S2]) was performed. Results The survey participation rate was 59% (389/658). Eighty-four percent of providers had improved scores in S2. Mean top-box scores improved from 0.63 to 0.76 (P < .001). Providers deemed less approachable by nonprovider staff were also deemed less approachable by their peers (r = 0.82; survey 1). Forty-four percent reported improvement in the safety culture in S2. Twenty-eight percent of providers reported making efforts to improve how they were perceived by others. Conclusions Provider approachability surveys are a safe, effective method of assessing and encouraging positive interactions that promote trust and influence positive communication. The process created an opportunity to identify and assist providers who were less approachable.
Eliminating Creatine Kinase–Myocardial Band Testing in Suspected Acute Coronary Syndrome
Jaffe, Allan S. , Ziegelstein, Roy C. , Trost, Jeffrey C. , Alvin, Matthew D. , Jaffe, Allan S.

Mayo Clinic

JAMA Internal Medicine | August 14, 2017 | Volume: 177 | Issue: 10 | Pages: 1508

10.1001/jamainternmed.2017.3597 | PMID 28806444 Get It

The Sound Quality of Cochlear Implants: Studies With Single-sided Deaf Patients
Dorman, Michael F. , Natale, Sarah Cook, Butts, Austin McRae, Zeitler, Daniel M. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | August 12, 2017 | Volume: 38 | Issue: 8 | Pages: e268-e273

10.1097/mao.0000000000001449 | PMID 28806337 Get It

Objective: The goal of the present study was to assess the sound quality of a cochlear implant for single-sided deaf (SSD) patients fit with a cochlear implant (CI). Background: One of the fundamental, unanswered questions in CI research is “what does an implant sound like?” Conventional CI patients must use the memory of a clean signal, often decades old, to judge the sound quality of their CIs. In contrast, SSD-CI patients can rate the similarity of a clean signal presented to the CI ear and candidate, CI-like signals presented to the ear with normal hearing. Methods: For Experiment 1 four types of stimuli were created for presentation to the normal hearing ear: noise vocoded signals, sine vocoded signals, frequency shifted, sine vocoded signals and band-pass filtered, natural speech signals. Listeners rated the similarity of these signals to unmodified signals sent to the CI on a scale of 0 to 10 with 10 being a complete match to the CI signal. For Experiment 2 multitrack signal mixing was used to create natural speech signals that varied along multiple dimensions. Results: In Experiment 1 for eight adult SSD-CI listeners, the best median similarity rating to the sound of the CI for noise vocoded signals was 1.9; for sine vocoded signals 2.9; for frequency upshifted signals, 1.9; and for band pass filtered signals, 5.5. In Experiment 2 for three young listeners, combinations of band pass filtering and spectral smearing lead to ratings of 10. Conclusion: The sound quality of noise and sine vocoders does not generally correspond to the sound quality of cochlear implants fit to SSD patients. Our preliminary conclusion is that natural speech signals that have been muffled to one degree or another by band pass filtering and/or spectral smearing provide a close, but incomplete, match to CI sound quality for some patients.
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Haricharan, Svasti , Punturi, Nindo , Singh, Purba , Holloway, Kimberly R. , Schmelz, Jacob , Schmidt, Cheryl, Lei, Jonathan T. , Li, Shunqiang , Huang, Shixia , Edwards, Dean P., Kavuri, Shyam M. , Bainbridge, Matthew N. , Cynthia, X. , Suman, Vera, Anurag, Meenakshi , Suman, Vera J. , Hunt, Kelly K. , Olson, John A. , Hoog, Jeremy , Ellis, Matthew J. , Lei, Jonathan T

Mayo Clinic

Cancer Discovery | August 11, 2017 | Volume: 7 | Issue: 10 | Pages: 1168-1183

10.1158/2159-8290.cd-16-1179 | PMID 28801307 Get It

Abstract Significant endocrine therapy–resistant tumor proliferation is present in ≥20% of estrogen receptor–positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismatch repair (MMR) complex (MLH1/3, PMS1/2), and demonstrate a direct role for MutL complex loss in resistance to all classes of endocrine therapy. We find that MutL deficiency in ER+ breast cancer abrogates CHK2-mediated inhibition of CDK4, a prerequisite for endocrine therapy responsiveness. Consequently, CDK4/6 inhibitors (CDK4/6i) remain effective in MutL-defective ER+ breast cancer cells. These observations are supported by data from a clinical trial where a CDK4/6i was found to strongly inhibit aromatase inhibitor–resistant proliferation of MutL-defective tumors. These data suggest that diagnostic markers of MutL deficiency could be used to direct adjuvant CDK4/6i to a population of patients with breast cancer who exhibit marked resistance to the current standard of care. Significance: MutL deficiency in a subset of ER+ primary tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy–resistant tumors. Therefore, markers of MutL dysregulation could guide CDK4/6 inhibitor use in the adjuvant setting, where the risk benefit ratio for untargeted therapeutic intervention is narrow. Cancer Discov; 7(10); 1168–83. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047